AU2016307370A1 - Transinfected lymphocytes for anti-tumor therapy - Google Patents

Transinfected lymphocytes for anti-tumor therapy Download PDF

Info

Publication number
AU2016307370A1
AU2016307370A1 AU2016307370A AU2016307370A AU2016307370A1 AU 2016307370 A1 AU2016307370 A1 AU 2016307370A1 AU 2016307370 A AU2016307370 A AU 2016307370A AU 2016307370 A AU2016307370 A AU 2016307370A AU 2016307370 A1 AU2016307370 A1 AU 2016307370A1
Authority
AU
Australia
Prior art keywords
cells
lymphocyte
cell
tumor
listeria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016307370A
Other languages
English (en)
Inventor
Balbino Alarcón Sanchez
Aranzazu CRUZ ADALIA
Guillermo RAMÍREZ SANTIAGO
Francisco SÁNCHEZ MADRID
Esteban VEIGA CHACÓN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Científicas
Autonomous University of Madrid
Hospital Universitario de la Princesa
Original Assignee
Consejo Superior de Investigaciones Científicas
Autonomous University of Madrid
Hospital Universitario de la Princesa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Científicas, Autonomous University of Madrid, Hospital Universitario de la Princesa filed Critical Consejo Superior de Investigaciones Científicas
Publication of AU2016307370A1 publication Critical patent/AU2016307370A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016307370A 2015-08-07 2016-08-08 Transinfected lymphocytes for anti-tumor therapy Abandoned AU2016307370A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201531177 2015-08-07
ESP201531177 2015-08-07
PCT/ES2016/070597 WO2017025657A1 (es) 2015-08-07 2016-08-08 Linfocitos transinfectados para terapia anti-tumoral

Publications (1)

Publication Number Publication Date
AU2016307370A1 true AU2016307370A1 (en) 2018-03-01

Family

ID=56936436

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016307370A Abandoned AU2016307370A1 (en) 2015-08-07 2016-08-08 Transinfected lymphocytes for anti-tumor therapy

Country Status (6)

Country Link
US (1) US20180228840A1 (cg-RX-API-DMAC10.html)
EP (1) EP3333255A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018522594A (cg-RX-API-DMAC10.html)
AU (1) AU2016307370A1 (cg-RX-API-DMAC10.html)
CA (1) CA2995021A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017025657A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12087428B2 (en) * 2020-12-29 2024-09-10 Kpn Innovations Llc Systems and methods for generating a body degradation reduction program

Also Published As

Publication number Publication date
WO2017025657A1 (es) 2017-02-16
CA2995021A1 (en) 2017-02-16
EP3333255A1 (en) 2018-06-13
US20180228840A1 (en) 2018-08-16
JP2018522594A (ja) 2018-08-16

Similar Documents

Publication Publication Date Title
Van der Most et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
Palucka et al. Dendritic cells and immunity against cancer
AU2007269245B2 (en) Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells
Palucka et al. Designing vaccines based on biology of human dendritic cell subsets
Romano et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo
US8475785B2 (en) Allogeneic cancer cell-based immunotherapy
KR20140052991A (ko) 항원-특이적 t 세포의 증식 방법
AU2015233542B2 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
KR20170121178A (ko) 보편적인 살해 t-세포
Florek et al. Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models
AU2018204834A1 (en) METHODS AND COMPOSITIONS FOR INHIBITION OF Treg CELLS
Huang et al. Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression
Keshavarz-Fathi et al. Cancer immunology
EP3333255A1 (en) Transinfected lymphocytes for anti-tumor therapy
CA2588685A1 (en) Alpha thymosin peptides as cancer vaccine adjuvants
WO2007120128A1 (en) Allogeneic cell therapy for treatment of opportunistic infection
Veiga et al. Lymphocytes transfectes pour therapie antitumorale
Aqui et al. Post-transplant adoptive T-cell immunotherapy
US11850279B2 (en) Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
Asada et al. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice
Kiura et al. In vivo anti-and pro-tumour activities of the TLR2 ligand FSL-1
Prophylactic Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models
Jæhger Preclinical Evaluation of Novel Drug Delivery Platforms for the Improvement of Adoptive T cell Therapy
Jacobs Towards immunotherapy in pediatric cancer patients.

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period